Treatment persistence with leukotriene receptor antagonists and inhaled corticosteroids

被引:23
作者
Dorais, M
Blais, L
Chabot, I
LeLorier, J
机构
[1] Hotel Dieu CHUM, Ctr Rech, Res Grp Pharmacoepidemiol & Pharmacoecon, Montreal, PQ H2W 1T7, Canada
[2] Univ Montreal, Montreal, PQ, Canada
[3] Merck Frosst Canada Ltd, Dept Hlth Econ & Outcomes Res, Montreal, PQ, Canada
关键词
leukotriene receptor antagonists; inhaled corticosteroids; persistence;
D O I
10.1081/JAS-200063007
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background. Leukotriene receptor antagonists (LTRAs) and inhaled corticosteroids (ICSs) must be taken continuously to control persistent asthma. We compared the use of LTRAs and ICSs in patients with similar level of asthma control at treatment initiation with particular attention to treatment persistence. Methods. Two cohorts of 15 to 45 year old patients with asthma were selected from the Quebec Health Insurance Plan Database between January 1, 1998, and December 31, 2000. We first identified new users of LTRAs and from the remaining patients, we selected new users of ICSs. The ICS patients were then one-to-one matched to LTRA patients on the use of short-acting beta(2)-agonists and oral corticosteroids in the year prior to the date of the first LTRA or ICS dispensation ( index date). We compared compliance to initial therapies using Cox proportional hazards models. Results. Each of the LTRA and ICS cohorts included 2200 patients. Multivariate model showed that compliance was significantly better for LTRAs than for ICSs [ adjusted rate ratio of treatment discontinuation (aRR), 0.46; 95% confidence interval (CI), 0.42 - 0.49]. If in both groups all medications filled were taken at the prescribed dose, the annual percent of days on therapy for LTRA users would have been twice that for ICS users (38% vs. 19%; p < 0.0001). Conclusion. The findings of this observational study indicate a far from optimal persistence to LTRAs and ICSs in asthmatic patients. The superior persistence to LTRAs might result in better effectiveness.
引用
收藏
页码:385 / 393
页数:9
相关论文
共 14 条
[1]   Ambulatory use of inhaled β2-agonists for the treatment of asthma in Quebec -: A population-based utilization review [J].
Blais, R ;
Grégoire, JP ;
Rouleau, R ;
Cartier, A ;
Bouchard, J ;
Boulet, LP .
CHEST, 2001, 119 (05) :1316-1321
[2]   Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma [J].
Bleecker, ER ;
Welch, MJ ;
Weinstein, SF ;
Kalberg, C ;
Johnson, M ;
Edwards, L ;
Rickard, KA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 105 (06) :1123-1129
[3]  
Boulet L P, 2001, Can Respir J, V8 Suppl A, p5A
[4]   A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy [J].
Bukstein, DA ;
Henk, HJ ;
Luskin, AT .
CLINICAL THERAPEUTICS, 2001, 23 (09) :1589-1600
[5]   Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial [J].
Busse, W ;
Raphael, GD ;
Galant, S ;
Kalberg, C ;
Goode-Sellers, S ;
Srebro, S ;
Edwards, L ;
Rickard, K .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (03) :461-468
[6]   Inhaled corticosteroids for asthma therapy - Patient compliance, devices, and inhalation technique [J].
Cochrane, MG ;
Bala, MV ;
Downs, KE ;
Mauskopf, J ;
Ben-Joseph, RH .
CHEST, 2000, 117 (02) :542-550
[7]   COMPARISON OF PATIENTS COMPLIANCE WITH PRESCRIBED ORAL AND INHALED ASTHMA MEDICATIONS [J].
KELLOWAY, JS ;
WYATT, RA ;
ADLIS, SA .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (12) :1349-1352
[8]  
LEE ET, 1992, WILEY SERIES PROBABI
[9]   Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma -: A randomized, controlled trial [J].
Malmstrom, K ;
Rodriguez-Gomez, G ;
Guerra, J ;
Villaran, C ;
Piñeiro, A ;
Wei, LX ;
Seidenberg, BC ;
Reiss, TF .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :487-+
[10]   Mild asthma. [J].
Naureckas, ET ;
Solway, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (17) :1257-1262